BioAge Labs IPO Securities Lawsuit
Analysis based on 12 articles · First reported Feb 01, 2025 · Last updated Feb 21, 2025
The market is negatively impacted by the news of a securities class action lawsuit against BioAge Labs, as it raises concerns about the company's transparency and the integrity of its IPO. This could lead to a decrease in investor confidence in BioAge Labs' stock and potentially affect other biotechnology companies undergoing clinical trials or IPOs.
A securities class action lawsuit has been filed against BioAge Labs in the United States — United States District Court for the Northern District of California. The lawsuit, publicized by Kessler Topaz Meltzer & Check, alleges that BioAge Labs made false and misleading statements in its registration statement and prospectus for its initial public offering on or about September 26, 2024. Specifically, the complaint claims that BioAge Labs failed to disclose the potential for liver transaminitis in its STRIDES Phase 1 trials and preclinical studies, and misrepresented the safety and expected outcomes of its STRIDES Phase 2 trial for azelaprag. Investors who purchased BioAge Labs stock during the Class Period have until March 10, 2025, to seek appointment as a lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard